ESPR - Esperion Therapeutics, Inc.
NEXT EARNINGS:
Mar 3, 2026
(in 6 days)
EPS Est: $0.23
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$9.00
DETAILS
HIGH:
$9.00
LOW:
$9.00
MEDIAN:
$9.00
CONSENSUS:
$9.00
UPSIDE:
172.73%
Market Cap:
651.85M
Volume:
2,701,512
Avg Volume:
5,281,606
52 Week Range:
0.69-4.18
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Beta:
1.11
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
304
IPO Date:
2013-06-26
EPS (TTM):
-0.28
P/E Ratio:
-7.96
Revenue (TTM):
332.31M
Total Assets:
343.82M
Total Debt:
591.21M
Cash & Equiv:
144.76M
Rev Growth (5Y):
17.5%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
7.7%
Debt/Equity:
-1.52
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-06 | $-0.16 | $-0.09 | -77.8% | $87.3M | $165.1M | -47.1% |
| 2025-08-05 | $-0.02 | $-0.17 | +88.2% | $82.4M | $82.5M | -0.1% |
| 2025-05-06 | $-0.21 | $-0.18 | -16.7% | $65.0M | $61.2M | +6.2% |
| 2025-03-04 | $-0.10 | $-0.14 | +28.6% | $69.1M | $51.7M | +33.7% |
| 2024-11-07 | $-0.15 | $-0.14 | -7.1% | $51.6M | $61.6M | -16.1% |
| 2024-08-12 | $-0.05 | $-0.15 | +66.7% | $73.8M | $49.1M | +50.5% |
| 2024-05-07 | $0.34 | $0.05 | +580.0% | $137.7M | $84.5M | +63.0% |
| 2024-02-27 | $-0.50 | $-0.53 | +5.7% | $32.2M | $28.7M | +12.4% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 332.31M | 116.33M | 75.47M | 78.45M | 227.55M | 148.36M | 184.47M | 0 | 0 | 0 | 0 | 4.98B |
| Net Income | (51.74M) | (209.25M) | (233.66M) | (269.11M) | (143.55M) | (97.17M) | (201.81M) | (166.99M) | (74.98M) | (49.78M) | (36.38M) | (26.09M) |
| EPS | -0.28 | -2.03 | -4.33 | -11.03 | -6.05 | -4.02 | -7.54 | -6.98 | -3.33 | -2.26 | -2.22 | -1.71 |
| Total Assets | 343.82M | 205.80M | 247.94M | 381.59M | 353.26M | 214.45M | 143.45M | 277.83M | 245.21M | 295.57M | 143.34M | 78.29M |
| Total Debt | 591.21M | 540.95M | 260.95M | 260.20M | 185.41M | 1.56M | 0 | 1.04M | 2.73M | 4.29M | 4.94M | 0 |
| Cash & Equivalents | 144.76M | 82.25M | 124.78M | 208.89M | 304.96M | 166.13M | 36.97M | 34.47M | 38.16M | 77.34M | 85.04M | 56.54M |
| Operating Cash Flow | (23.65M) | (135.49M) | (174.83M) | (263.81M) | (85.18M) | (70.34M) | (148.64M) | (131.30M) | (47.73M) | (38.16M) | (32.02M) | (18.11M) |
| Free Cash Flow | (23.97M) | (135.49M) | (174.83M) | (263.81M) | (98.55M) | (71.29M) | (148.79M) | (131.32M) | (47.82M) | (38.48M) | (32.89M) | (18.14M) |
| FCF per Share | -0.13 | -1.31 | -2.63 | -9.13 | -3.59 | -2.63 | -5.56 | -5.49 | -2.12 | -1.75 | -2.01 | -1.19 |
| Book Value | (388.72M) | (454.99M) | (323.78M) | (196.94M) | (96.13M) | 19.95M | (598.10M) | 244.69M | 228.60M | 287.26M | 133.55M | 74.09M |
| Cash & ST Investments | 144.76M | 82.25M | 166.86M | 259.33M | 304.96M | 200.78M | 36.97M | 34.47M | 38.16M | 77.34M | 85.04M | 60.06M |
| ROC Equity | N/A | N/A | N/A | N/A | N/A | -4.87 | N/A | -0.68 | -0.33 | -0.17 | -0.27 | -0.35 |